Skip to main content

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

2024 Finnish NordDRG system came into force

On January 1, 2024, the annual update of the Finnish NordDRG system came into force. There are 981 DRGs in the 2024 DRG system, compared to 947 DRGs in 2023. Among other changes, 63 new DRGs were introduced, and 29 DRGs were discontinued

Some examples of new DRGs are provided below:

  • P01 Surgical procedure related to gender identity;
  • P01O Surgical procedure related to gender identity, short treatment.
  • P02O Neuromodulation therapy, short treatment; 
  • 359R Other uterine and appendages procedures in benign lesion;
  • 843V Biopsy of prostate, testicle, penis, etc., short treatment;

See the full details here (can be obtained per request).

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.